Merck Animal Health will invest $895 million to expand vaccine manufacturing and R&D in Kansas, while Lilly is committing ...

Merck (NYSE:MRK) on Thursday announced plans to invest $895M to expand a manufacturing facility in Kansas, becoming the ...

A new manufacturing plant in De Soto will be a Center of Excellence for the global company, along with expanded R&D ...

Merck maintained its 2025 full-year revenue ... supported by a robust pipeline and significant investments in manufacturing and R&D. Management emphasized a focus on navigating short-term ...

Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.

Rahway, New Jersey Friday, May 9, 2025, 09:00 Hrs [IST] ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

The investment comprising $860M allotted for the site's existing production facility and $35M allocated for R&D labs is set to boost the production capacity of Merck Animal Health’s large ...

The $895 million capital expansion will be constructed on an existing Merck-owned property that is the site of its biologics facility in De Soto, Kansas. It includes an $860 million investment in ...